Cover Image
市場調查報告書

嚴重急性呼吸道症候群 (SARS) 犬冠狀病毒感染疾病:開發平台分析

Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 255961
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
嚴重急性呼吸道症候群 (SARS) 犬冠狀病毒感染疾病:開發平台分析 Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 52 Pages
簡介

嚴重急性呼吸道症候群 (SARS)是犬冠狀病毒科的病毒所引起,嚴重時可能致死的可怕病毒傳染病。症狀有咳嗽、發冷和發抖、頭痛、肌肉痛、腹瀉、暈眩、噁心和嘔吐等。危險因素有免疫系統的遺傳基因變異,與感染者的緊密接觸等。

本報告提供嚴重急性呼吸道症候群 (SARS) 犬冠狀病毒感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

嚴重急性呼吸道症候群 (SARS) 犬冠狀病毒感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • CEL-SCI Corporation
  • GeneCure LLC
  • Humabs BioMed SA
  • Inovio Pharmaceuticals, Inc.
  • Nanotherapeutics, Inc.
  • Novavax, Inc.
  • Phelix Therapeutics, LLC
  • Protein Sciences Corporation

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • CEL-1000
  • D-3252
  • Drugs to Inhibit Cathepsin L for Infectious Diseases
  • FDX-000
  • INO-4500
  • LCA-60
  • middle east respiratory syndrome vaccine + severe acute respiratory syndrome vaccine
  • ML-188
  • Monoclonal Antibody for SARS Virus Infections
  • RBD-219N1
  • SARS (virus like particle) vaccine
  • SARS vaccine
  • SARS vaccine
  • severe acute respiratory syndrome vaccine
  • Small Molecule to Inhibit Cathepsin L for SARS and Ebola Viral Infections
  • SSYA-10001
  • thiocarbazate

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9645IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.

Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Severe Acute Respiratory Syndrome (SARS) - Overview
    • Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
    • 3-V Biosciences Inc
    • Atriva Therapeutics GmbH
    • Autoimmune Technologies LLC
    • CEL-SCI Corp
    • Fab'entech SA
    • GeneCure LLC
    • Gilead Sciences Inc
    • Nanotherapeutics Inc
    • Novavax Inc
    • Oncovir Inc
    • Phelix Therapeutics LLC
    • Protein Sciences Corp
  • Severe Acute Respiratory Syndrome (SARS) - Drug Profiles
    • ATR-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSW-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-3252 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-5734 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ML-188 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for SARS Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Poly-ICLC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SARS (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SSYA-10001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TVB-3567 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Severe Acute Respiratory Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects
  • Severe Acute Respiratory Syndrome (SARS) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by 3-V Biosciences Inc, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Atriva Therapeutics GmbH, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Autoimmune Technologies LLC, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by CEL-SCI Corp, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Fab'entech SA, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by GeneCure LLC, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Gilead Sciences Inc, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Nanotherapeutics Inc, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Novavax Inc, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Oncovir Inc, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Phelix Therapeutics LLC, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Pipeline by Protein Sciences Corp, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Severe Acute Respiratory Syndrome (SARS) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top